Overview
Pamela S Douglas MD is the Ursula Geller Professor of Research in Cardiovascular Diseases in the Department of Medicine at Duke University and Director of the Multimodality Imaging Program at Duke Clinical Research Institute. During her 30+ years of experience she has led several landmark multicenter government studies and pivotal industry clinical trials along with outcomes research studies. She is renowned for her scientific and policy work in improving the quality and appropriateness of imaging in clinical care, clinical trials and registries and through development and dissemination of national standards for imaging utilization, informatics and analysis. She has been among the pioneers in a number of areas including heart disease in women, sports cardiology, and cardio-oncology. Dr. Douglas’ wealth of experience includes authorship of over 400 peer reviewed manuscripts and 30 practice guidelines, and service as the President of the American College of Cardiology, President of the American Society of Echocardiography, and Chief of Cardiology at both the University of Wisconsin and Duke University. She has also previously served on the faculties of the University of Pennsylvania and Harvard University. She currently serves on the External Advisory Council of the National Heart, Lung and Blood Institute and the Scientific Advisory Board of the Patient Advocate Foundation.
Current Appointments & Affiliations
Recent Publications
Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.
Journal Article Am J Med Open · June 2025 BACKGROUND: Returning results to research participants is increasingly recognized as an ethical mandate, yet little is known about best practices to optimally communicate urgent or emergent results. METHODS: We describe the development of and experience wi ... Full text Link to item CiteThe Distribution of Coronary Plaque Volumes across CAD-RADS Categories: A PRECISE Substudy.
Journal Article Radiol Cardiothorac Imaging · June 2025 Full text Link to item CiteEffects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.
Journal Article The lancet. HIV · June 2025 BackgroundIn the REPRIEVE trial of statin therapy in people with HIV, pitavastatin reduced major adverse cardiovascular events (MACE) among those with low-to-moderate risk of cardiovascular disease (CVD). We aimed to investigate associations betwe ... Full text CiteRecent Grants
Molecular predictors of cardiovascular events and resilience in chronic coronary artery disease
ResearchCo Investigator · Awarded by NYU Langone Medical Center · 2023 - 2028Pericoronary adipose tissue density a novel CT-derived marker of local inflammation and coronary artery disease in patients living with HIV
ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2023 - 2027Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN)
ResearchCo Investigator · Awarded by Aga Khan University · 2021 - 2026View All Grants